236 related articles for article (PubMed ID: 16391719)
1. Prostratin as a new therapeutic agent targeting HIV viral reservoirs.
Hezareh M
Drug News Perspect; 2005 Oct; 18(8):496-500. PubMed ID: 16391719
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation.
Márquez N; Calzado MA; Sánchez-Duffhues G; Pérez M; Minassi A; Pagani A; Appendino G; Diaz L; Muñoz-Fernández MA; Muñoz E
Biochem Pharmacol; 2008 Mar; 75(6):1370-80. PubMed ID: 18241838
[TBL] [Abstract][Full Text] [Related]
3. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART.
Kulkosky J; Culnan DM; Roman J; Dornadula G; Schnell M; Boyd MR; Pomerantz RJ
Blood; 2001 Nov; 98(10):3006-15. PubMed ID: 11698284
[TBL] [Abstract][Full Text] [Related]
4. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes.
Rullas J; Bermejo M; García-Pérez J; Beltán M; González N; Hezareh M; Brown SJ; Alcamí J
Antivir Ther; 2004 Aug; 9(4):545-54. PubMed ID: 15456086
[TBL] [Abstract][Full Text] [Related]
5. Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies.
Demonté D; Quivy V; Colette Y; Van Lint C
Biochem Pharmacol; 2004 Sep; 68(6):1231-8. PubMed ID: 15313421
[TBL] [Abstract][Full Text] [Related]
6. Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue.
Biancotto A; Grivel JC; Gondois-Rey F; Bettendroffer L; Vigne R; Brown S; Margolis LB; Hirsch I
J Virol; 2004 Oct; 78(19):10507-15. PubMed ID: 15367617
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
Reuse S; Calao M; Kabeya K; Guiguen A; Gatot JS; Quivy V; Vanhulle C; Lamine A; Vaira D; Demonte D; Martinelli V; Veithen E; Cherrier T; Avettand V; Poutrel S; Piette J; de Launoit Y; Moutschen M; Burny A; Rouzioux C; De Wit S; Herbein G; Rohr O; Collette Y; Lambotte O; Clumeck N; Van Lint C
PLoS One; 2009 Jun; 4(6):e6093. PubMed ID: 19564922
[TBL] [Abstract][Full Text] [Related]
8. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
9. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
Pomerantz RJ
Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
[TBL] [Abstract][Full Text] [Related]
10. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy.
Kulkosky J; Pomerantz RJ
Clin Infect Dis; 2002 Dec; 35(12):1520-6. PubMed ID: 12471572
[TBL] [Abstract][Full Text] [Related]
11. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.
Kulkosky J; Nunnari G; Otero M; Calarota S; Dornadula G; Zhang H; Malin A; Sullivan J; Xu Y; DeSimone J; Babinchak T; Stern J; Cavert W; Haase A; Pomerantz RJ
J Infect Dis; 2002 Nov; 186(10):1403-11. PubMed ID: 12404155
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
Redel L; Le Douce V; Cherrier T; Marban C; Janossy A; Aunis D; Van Lint C; Rohr O; Schwartz C
J Leukoc Biol; 2010 Apr; 87(4):575-88. PubMed ID: 19801499
[TBL] [Abstract][Full Text] [Related]
13. Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.
Quivy V; De Walque S; Van Lint C
Subcell Biochem; 2007; 41():371-96. PubMed ID: 17484137
[TBL] [Abstract][Full Text] [Related]
14. Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo.
Beans EJ; Fournogerakis D; Gauntlett C; Heumann LV; Kramer R; Marsden MD; Murray D; Chun TW; Zack JA; Wender PA
Proc Natl Acad Sci U S A; 2013 Jul; 110(29):11698-703. PubMed ID: 23812750
[TBL] [Abstract][Full Text] [Related]
15. In vitro reactivation of human immunodeficiency virus 1 from latently infected, resting CD4+ T cells after bacterial stimulation.
Moriuchi H; Moriuchi M; Mizell SB; Ehler LA; Fauci AS
J Infect Dis; 2000 Jun; 181(6):2041-4. PubMed ID: 10837189
[TBL] [Abstract][Full Text] [Related]
16. SJ23B, a jatrophane diterpene activates classical PKCs and displays strong activity against HIV in vitro.
Bedoya LM; Márquez N; Martínez N; Gutiérrez-Eisman S; Alvarez A; Calzado MA; Rojas JM; Appendino G; Muñoz E; Alcamí J
Biochem Pharmacol; 2009 Mar; 77(6):965-78. PubMed ID: 19100719
[TBL] [Abstract][Full Text] [Related]
17. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
18. Effects of diterpenes from latex of Euphorbia lactea and Euphorbia laurifolia on human immunodeficiency virus type 1 reactivation.
Avila L; Perez M; Sanchez-Duffhues G; Hernández-Galán R; Muñoz E; Cabezas F; Quiñones W; Torres F; Echeverri F
Phytochemistry; 2010 Feb; 71(2-3):243-8. PubMed ID: 19897215
[TBL] [Abstract][Full Text] [Related]
19. StpC-based gene therapy targeting latent reservoirs of HIV-1.
Turner LS; Tsygankov AY; Henderson EE
Antiviral Res; 2006 Dec; 72(3):233-41. PubMed ID: 16891001
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
